WO2005023328A3 - Methods for intradermal delivery of therapeutics agents - Google Patents

Methods for intradermal delivery of therapeutics agents Download PDF

Info

Publication number
WO2005023328A3
WO2005023328A3 PCT/US2004/019118 US2004019118W WO2005023328A3 WO 2005023328 A3 WO2005023328 A3 WO 2005023328A3 US 2004019118 W US2004019118 W US 2004019118W WO 2005023328 A3 WO2005023328 A3 WO 2005023328A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
methods
delivery
present
improved
Prior art date
Application number
PCT/US2004/019118
Other languages
French (fr)
Other versions
WO2005023328A2 (en
Inventor
Ronald J Pettis
Alfred Harvey
Robert Campbell
John Mikszta
John Brittingham
Original Assignee
Becton Dickinson Co
Ronald J Pettis
Alfred Harvey
Robert Campbell
John Mikszta
John Brittingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co, Ronald J Pettis, Alfred Harvey, Robert Campbell, John Mikszta, John Brittingham filed Critical Becton Dickinson Co
Priority to BRPI0414014-1A priority Critical patent/BRPI0414014A/en
Priority to MXPA06002159A priority patent/MXPA06002159A/en
Priority to CA002536669A priority patent/CA2536669A1/en
Priority to JP2006524624A priority patent/JP2007503435A/en
Priority to EP04776618A priority patent/EP1658078A4/en
Priority to AU2004270113A priority patent/AU2004270113A1/en
Publication of WO2005023328A2 publication Critical patent/WO2005023328A2/en
Publication of WO2005023328A3 publication Critical patent/WO2005023328A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to methods and devices for delivering one or more biologically active agents, particularly therapeutic agents, the intradermal compartment of a subject’s skin. The present invention provides an improved method of delivery of biologically active agents, such as therapeutic agents, through lymphatic vasculature accessed by intradermal delivery. Therapeutic agents to be delivered in accordance with the present invention include, but are not limited ton antineoplastic agents, chemotherapeutic agents, antibodies, antibiotics, anti-angiogenesis agents, anti-inflammatory agents, and immunotherapeutic agents. Therapeutic agents delivered in accordance with the present invention have improved bioavailability, including improved systemic distribution and improved delivery to particular tissues. Therapeutic agents, delivered in accordance with the methods of the invention have an improved clinical utility and therapeutic efficacy relative to other drug delivery methods, including intraperitoneal, intramuscular and subcutaneous delivery. The methods of the present invention provide benefits and improvements over convention drug delivery methods including dose sparing, increased drug efficacy, reduced side effects, reduced metastatic potential and prolonged survival.
PCT/US2004/019118 2003-08-26 2004-06-14 Methods for intradermal delivery of therapeutics agents WO2005023328A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0414014-1A BRPI0414014A (en) 2003-08-26 2004-06-14 methods for intradermal delivery of therapeutic agents
MXPA06002159A MXPA06002159A (en) 2003-08-26 2004-06-14 Methods for intradermal delivery of therapeutics agents.
CA002536669A CA2536669A1 (en) 2003-08-26 2004-06-14 Methods for intradermal delivery of therapeutics agents
JP2006524624A JP2007503435A (en) 2003-08-26 2004-06-14 Intradermal delivery of therapeutics
EP04776618A EP1658078A4 (en) 2003-08-26 2004-06-14 Methods for intradermal delivery of therapeutics agents
AU2004270113A AU2004270113A1 (en) 2003-08-26 2004-06-14 Methods for intradermal delivery of therapeutics agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49770203P 2003-08-26 2003-08-26
US60/497,702 2003-08-26
US55019704P 2004-03-03 2004-03-03
US60/550,197 2004-03-03

Publications (2)

Publication Number Publication Date
WO2005023328A2 WO2005023328A2 (en) 2005-03-17
WO2005023328A3 true WO2005023328A3 (en) 2005-11-10

Family

ID=34278560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/019118 WO2005023328A2 (en) 2003-08-26 2004-06-14 Methods for intradermal delivery of therapeutics agents

Country Status (8)

Country Link
US (1) US20050180952A1 (en)
EP (1) EP1658078A4 (en)
JP (1) JP2007503435A (en)
AU (1) AU2004270113A1 (en)
BR (1) BRPI0414014A (en)
CA (1) CA2536669A1 (en)
MX (1) MXPA06002159A (en)
WO (1) WO2005023328A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0526849A (en) * 1991-07-17 1993-02-02 Hitachi Building Syst Eng & Service Co Ltd Magnetic flaw detector
US20060018877A1 (en) * 2001-06-29 2006-01-26 Mikszta John A Intradermal delivery of vacccines and therapeutic agents
JP2004531578A (en) * 2001-06-29 2004-10-14 ベクトン・ディキンソン・アンド・カンパニー Intradermal delivery of vaccines and gene therapeutics by microcannula
AU2004264839B2 (en) * 2003-06-13 2009-06-04 Becton, Dickinson And Company Improved intra-dermal delivery of biologically active agents
US20050196380A1 (en) * 2004-03-08 2005-09-08 Mikszta John A. Method for delivering therapeutic proteins to the intradermal compartment
MX2007002925A (en) 2004-09-10 2007-08-14 Becton Dickinson Co Reconstituting infusion device.
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
KR100700869B1 (en) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 The stabilized parathyroid hormone composition comprising parathyroid hormone buffer and stabilizing agent
GT200600397A (en) * 2005-09-07 2007-08-28 TOPIC FORMULAS CONTAINING O-DESMETIL VENLAFAXINA (ODV) OR ITS SALTS
US20100226920A1 (en) * 2006-03-27 2010-09-09 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
WO2008014216A1 (en) * 2006-07-28 2008-01-31 St. Jude Children's Research Hospital Method for treating ocular cancer
US7811254B2 (en) * 2006-10-18 2010-10-12 Meridian Medical Technologies, Inc. Autoinjector with needle depth adapter
EP2214709A4 (en) * 2007-11-08 2011-05-11 Univ Utah Res Found Use of angiogenesis antagonists in conditions of abnormal venous proliferation
US20100311671A1 (en) * 2009-03-25 2010-12-09 Kai Pharmaceuticals Transdermal delivery of pkc modulatory peptides through microporated skin
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
DK2649998T3 (en) 2009-11-06 2015-05-04 Aerpio Therapeutics Inc Prolyl hydroxylase inhibitors
US8814831B2 (en) * 2010-11-30 2014-08-26 Becton, Dickinson And Company Ballistic microneedle infusion device
US8784383B2 (en) 2010-11-30 2014-07-22 Becton, Dickinson And Company Insulin pump dermal infusion set having partially integrated mechanized cannula insertion with disposable activation portion
EP3574950B1 (en) 2011-10-27 2021-02-17 Sorrento Therapeutics, Inc. Transdermal delivery of high viscosity bioactive agents
JP6929829B2 (en) * 2015-07-24 2021-09-01 ソレント・セラピューティクス・インコーポレイテッド Drug delivery device
EP3325080B1 (en) 2015-07-24 2021-09-01 Sorrento Therapeutics, Inc. Methods for better delivery of active agents to tumors
IL249795B (en) * 2016-02-05 2020-01-30 Grifols Worldwide Operations Ltd Intradermal administration of immunoglobulin g preparation
KR102168749B1 (en) * 2017-11-17 2020-10-22 한양대학교 산학협력단 Brain drug delivery device through nasal cavity and brain drug delivery method through nasal cavity
JP2021525576A (en) * 2018-05-31 2021-09-27 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Drug delivery method targeting the lymphatic system
WO2021061822A1 (en) * 2019-09-23 2021-04-01 Aquavit Pharmaceuticals, Inc. Methods for treating neoplastic conditions of the skin
US11202753B1 (en) 2020-03-06 2021-12-21 Aquavit Pharmaceuticals, Inc. Systems and methods for generating immune responses in subjects using microchannel delivery devices

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183333A1 (en) * 2000-03-29 2002-12-05 Shah Sudhir V. Compositions and methods for chemotherapy having reduced nephrotoxicity
US6509321B1 (en) * 1998-09-15 2003-01-21 Genetics Institute, Inc. Treatment of Kaposi's sarcoma with IL-12

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2619962A (en) * 1948-02-19 1952-12-02 Res Foundation Vaccination appliance
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US3914097A (en) * 1974-02-01 1975-10-21 Eastman Kodak Co Sheet guide and cooling apparatus
US4270537A (en) * 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
IE53703B1 (en) * 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
CA1283827C (en) * 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
AU614092B2 (en) * 1987-09-11 1991-08-22 Paul Max Grinwald Improved method and apparatus for enhanced drug permeation of skin
EP0429842B1 (en) * 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Device for the transdermal administration of protein or peptide drug
US5098389A (en) * 1990-06-28 1992-03-24 Becton, Dickinson And Company Hypodermic needle assembly
US5527288A (en) * 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5279544A (en) * 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
US5156591A (en) * 1990-12-13 1992-10-20 S. I. Scientific Innovations Ltd. Skin electrode construction and transdermal drug delivery device utilizing same
TW279133B (en) * 1990-12-13 1996-06-21 Elan Med Tech
SE9102652D0 (en) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
US5279552A (en) * 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
CA2132277C (en) * 1993-10-22 2005-05-10 Giorgio Cirelli Injection device
US5997501A (en) * 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
US5591139A (en) * 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
US5582591A (en) * 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
IE72524B1 (en) * 1994-11-04 1997-04-23 Elan Med Tech Analyte-controlled liquid delivery device and analyte monitor
AU5740496A (en) * 1995-05-22 1996-12-11 General Hospital Corporation, The Micromechanical device and method for enhancing delivery of compounds through the skin
US5801057A (en) * 1996-03-22 1998-09-01 Smart; Wilson H. Microsampling device and method of construction
NZ333321A (en) * 1996-06-10 2000-08-25 Elan Corp Plc Needle for subcutaneous delivery of fluids, slots in needle near tip
US5871158A (en) * 1997-01-27 1999-02-16 The University Of Utah Research Foundation Methods for preparing devices having metallic hollow microchannels on planar substrate surfaces
US5928207A (en) * 1997-06-30 1999-07-27 The Regents Of The University Of California Microneedle with isotropically etched tip, and method of fabricating such a device
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
IE970782A1 (en) * 1997-10-22 1999-05-05 Elan Corp An improved automatic syringe
US6482176B1 (en) * 1997-11-27 2002-11-19 Disetronic Licensing Ag Method and device for controlling the introduction depth of an injection needle
IT1298087B1 (en) * 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
US5957895A (en) * 1998-02-20 1999-09-28 Becton Dickinson And Company Low-profile automatic injection device with self-emptying reservoir
US6503231B1 (en) * 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB9827102D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
DE19934433A1 (en) * 1999-07-22 2001-01-25 Merck Patent Gmbh New N-(indolyl-carbonyl)-N'-ethyl-piperazine derivatives, are 5-HT-2A receptor antagonists useful e.g. for treating schizophrenia, depression, Parkinson's disease, Alzheimer's disease or anorexia
US6319224B1 (en) * 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US8465468B1 (en) * 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
US20020095134A1 (en) * 1999-10-14 2002-07-18 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
US20020193740A1 (en) * 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6537242B1 (en) * 2000-06-06 2003-03-25 Becton, Dickinson And Company Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance
JP2004525713A (en) * 2001-04-13 2004-08-26 ベクトン・ディキンソン・アンド・カンパニー Methods and devices for administering substances into the intradermal layer of the skin for systemic absorption
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
US20050096331A1 (en) * 2001-12-21 2005-05-05 Das Saibal K. Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
AU2004264839B2 (en) * 2003-06-13 2009-06-04 Becton, Dickinson And Company Improved intra-dermal delivery of biologically active agents
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509321B1 (en) * 1998-09-15 2003-01-21 Genetics Institute, Inc. Treatment of Kaposi's sarcoma with IL-12
US20020183333A1 (en) * 2000-03-29 2002-12-05 Shah Sudhir V. Compositions and methods for chemotherapy having reduced nephrotoxicity

Also Published As

Publication number Publication date
MXPA06002159A (en) 2006-05-22
CA2536669A1 (en) 2005-03-17
US20050180952A1 (en) 2005-08-18
EP1658078A4 (en) 2009-05-06
BRPI0414014A (en) 2006-10-24
AU2004270113A1 (en) 2005-03-17
WO2005023328A2 (en) 2005-03-17
JP2007503435A (en) 2007-02-22
EP1658078A2 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
WO2005023328A3 (en) Methods for intradermal delivery of therapeutics agents
WO2005016401A3 (en) Improved intra-dermal delivery of biologically active agents
WO2005115360A3 (en) Formulations of anti-pain agents and methods of using the same
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2006127962A3 (en) Particulate formulations for intradermal delivery of biologically active agents
WO2004096998A3 (en) Nanoparticular tumor targeting and therapy
WO2001091728A3 (en) Nanoemulsion formulations
WO2005084710A3 (en) Nanocell drug delivery system
WO2004105782A3 (en) Drug delivery systems for tumor targeting ngr-molecules and uses thereof
WO2006099169A3 (en) Novel liposome compositions
WO2001028591A3 (en) Injection vehicle for polymer-based formulations
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
WO2010059253A3 (en) Methods and compositions for localized agent delivery
NZ593641A (en) Extended soluble ph20 polypeptides and uses thereof
MX359410B (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors.
TW200605908A (en) Liposomes useful for drug delivery
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
CL2011001445A1 (en) Compound 3- (4-Chloro-2-fluorobenzyl) -2-methyl-n- (5-methyl-1h-pyrazol-3-yl) -8- (morpholinomethyl) imidazo [1,2-b] pyridazine-6- amine; pharmaceutical composition; and use in the treatment of chronic myeloproliferative disorders and in the treatment of glioblastoma, breast cancer, multiple myeloma, prostate cancer and leukemia
WO2004071538A3 (en) Topical delivery of cosmetic agents
WO2008116053A3 (en) Fap-activated chemotherapeutic compounds, and methods of use thereof
WO2009073050A3 (en) Use of curcumin to block brain tumor formation in vivo
TW200635949A (en) Tripeptide and tetrapeptide sulfones
WO2005086773A3 (en) A method for delivering therapeutic proteins to the intradermal compartment
WO2009006473A3 (en) Pro-soft polypeptide proteasome inhibitors, and methods of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480029970.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2536669

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004270113

Country of ref document: AU

Ref document number: PA/a/2006/002159

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006524624

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004776618

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004270113

Country of ref document: AU

Date of ref document: 20040614

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 682/KOLNP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004776618

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0414014

Country of ref document: BR